Growth hormone secretagogues have a potentially lower risk
For Specific Therapeutic Conditions: In clinical studies for conditions like Parkinson's disease, dosages have been evaluated at 1,400 mg three times per week for four weeks
For starters, reducing intake of common reflux triggers is often still helpful
Spending on glucagon-like peptide-1 receptor agonists among US adults, JAMA Network Open (2025) H.R.4818 treat and reduce obesity act of 2023, Congress.gov (2023) Anti-obesity drugs will not be covered by Medicare and Medicaid in 2026, American College of Gastroenterology (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The write-up also captures that, although the number of adverse event mentions rose over time, the proportion of posts focusing on side effects declined, reflecting a shift in online conversations toward other aspects of these drugs
Du X, Kleitz F, Li X, Huang H, Zhang X, Qiao S-Z